Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

September 1, 2026Posted inBiotechnology

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases.

Post navigation

Previous Post
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
Next Post
Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences lilly-looks-beyond-obesity-with-up-to-$2.9b-acquisition-of-merida-biosciences

Recent Posts

  • Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences
  • Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
  • ArsenalBio sheds most of staff in pivot to in vivo CAR-T
  • Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
  • Novocure hit by cyberattack exposing patient data

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top